Pfizer has been relentlessly reducing its stake in health product giant
Haleon, with large chunks of shares sold adding up to billions. Despite some price target downgrades by
Morgan Stanley and concerns over the oral care growth and competition, Haleon continues to be favored for its top-line growth. Interestingly, while Pfizer sells, investment entities like
Ritholtz Wealth Management,
Park Avenue Securities LLC, and
Procyon Advisors LLC have been actively buying Haleon shares. Furthermore, there's been an increase in
BlackRock's stake in the company suggesting realignment of major holdings. Apart from the share shuffle, Haleon also witnessed an executive share option grant and several executives acquired shares as part of their reward plan. Haleon undertook its own strategic measures with a share buyback program and expanded its stake in a Chinese joint venture. Despite mixed financials, the company continues to be owned 72% by institutional shareholders, shedding light on its strategic importance in portfolios.
Haleon Stocks News Analytics from Mon, 18 Mar 2024 07:00:00 GMT to Thu, 23 Jan 2025 13:07:52 GMT -
Rating 5
- Innovation 3
- Information 6
- Rumor -5
